(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 December 2011 (22.12.2011)

PCT

(10) International Publication Number
WO 2011/158053 A1

(51) **International Patent Classification**:
C07D 413/06 (2006.01) ***A61K 31/5377*** (2006.01)
A61P 9/08 (2006.01)

(21) **International Application Number**:
PCT/HU2011/000057

(22) **International Filing Date**:
17 June 2011 (17.06.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
P1000325 18 June 2010 (18.06.2010) HU

(71) **Applicant** *(for all designated States except US)*: **NANOFORM CARDIOVASCULAR THERAPEUTICS LTD.** [GB/GB]; 100 Fetter Lane, London EC4A 1BN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **FILIPCSEI, Genovéva** [HU/HU]; Petneházy utca 66. I/103., H-1135 Budapest (HU). **ÖTVÖS, Zsolt** [HU/HU]; Raisio utca 4, I/2., H-6640 Csongrád (HU). **HELTOVICS, Gábor** [HU/HU]; Bíró utca 12., H-1122 Budapest (HU). **DARVAS, Ferenc** [HU/HU]; Lisznyai utca 15., H-1016 Budapest (HU).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/158053 A1

(54) **Title**: NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

(57) **Abstract**: The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.